Current status and future perspectives of patient-reported outcome research in clinical trials for patients with breast cancer in Japan
Tóm tắt
The aim of healthcare providers is to help patients regain their health and/or maintain or increase their happiness. The quality of healthcare can be assessed objectively by using indices such as survival rates, but subjective assessment is sometimes more important than objective evaluation, because whether patients feel healthy or happy or not is their major concern. Quality of life (QOL) research is a typical approach to subjective assessment of health. Self-administered health-related QOL (HRQOL) questionnaires are used to obtain patient-reported outcome (PRO) data. PRO is defined by the US Food and Drug Administration (FDA) as any report of the status of a patient’s health condition that comes directly from the patient, without interpretation of the patient’s response by a clinician or anyone else. PRO data are regarded as more accurate than clinician-rated ones in terms of assessing patients’ symptoms and HRQOL. The Comprehensive Support Project for Health Outcome Research of the Public Health Research Foundation has conducted much PRO research in collaboration with the Comprehensive Support Project for Oncology Research, especially in randomized controlled trials (RCTs). Here, we review the results of PRO research in RCTs conducted in Japan and examine future perspectives in this field.
Tài liệu tham khảo
Velikova G, Wright P, Smith AB, Stark D, Perren T, Brown J, et al. Self-reported quality of life of individual cancer patients: concordance of results with disease course and medical records. J Clin Oncol. 2001;19:2064–73.
Fromme EK, Eilers KM, Mori M, Hsieh Y-C, Beer TM. How accurate is clinician reporting of chemotherapy adverse effects? A comparison with patient-reported symptoms from the quality-of-life questionnaire C30. J Clin Oncol. 2004;22:3485–90.
Watanabe T, Sano M, Takashima S, Kitaya T, Tokuda Y, Yoshimoto M, et al. Oral uracil and tegafur compared with classic cyclophosphamide, methotrexate, fluorouracil as postoperative chemotherapy in patients with node-negative, high-risk breast cancer: National Surgical Adjuvant Study for Breast Cancer 01 trial. J Clin Oncol. 2009;27:1368–74.
Groenvold M, Klee MC, Sprangers MA, Aaronson NK. Validation of the EORTC QLQ-C30 quality of life questionnaire through combined qualitative and quantitative assessment of patient-observer agreement. J Clin Epidemiol. 1997;50:441–50.
Sprangers MA, Groenvold M, Arraras JI, Franklin J, te Velde A, Muller M, et al. The European Organization for Research and Treatment of Cancer breast cancer-specific quality-of-life questionnaire module: first results from a three country field study. J Clin Oncol. 1996;14:2756–68.
Brady MJ, Cella DF, Mo F, Bonomi AE, Tulsky DS, Lloyd SR, et al. Reliability and validity of the Functional Assessment of Cancer Therapy-Breast quality-of-life instrument. J Clin Oncol. 1997;15:974–86.
Cella DF, Tulsky DS, Gray G, Sarafian B, Linn E, Bonomi A, et al. The Functional Assessment of Cancer Therapy scale: development and validation of the general measure. J Clin Oncol. 1993;11:570–9.
Watanabe T, Kuranami M, Inoue K, Masuda N, Aogi K, Ohno S, et al. Docetaxel is superior to paclitaxel given every three weeks in postoperative patients with node-positive breast cancer: results of the final analyses of the NSAS-BC (National Surgical Adjuvant Study of Breast Cancer) 02 trial from Japan. Cancer Res. 2011;71:140s–1s.
Cella D, Peterman A, Hudgens S, Webster K, Socinski MA. Measuring the side effects of taxane therapy in oncology: the functional assessment of cancer therapy-taxane (FACT-taxane). Cancer. 2003;98:822–31.
Hausheer FH, Schilsky RL, Bain S, Berghorn EJ, Lieberman F. Diagnosis, management, and evaluation of chemotherapy-induced peripheral neuropathy. Semin Oncol. 2006;33:15–49.
Shimozuma K, Ohashi Y, Takeuchi A, Aranishi T, Morita S, Kuroi K, et al. Patient-reported taxane-induced peripheral neuropathy and health-related quality-of-life in post-operative breast cancer patients undergoing adjuvant chemotherapy: N-SAS BC 02, a randomized clinical trial (submitted).
Calhoun EA, Welshman EE, Chang CH, Lurain JR, Fishman DA, Hunt TL, et al. Psychometric evaluation of the Functional Assessment of Cancer Therapy/Gynecologic Oncology Group-Neurotoxicity (Fact/GOG-Ntx) questionnaire for patients receiving systemic chemotherapy. Int J Gynecol Cancer. 2003;13:741–8.
Shimozuma K, Ohashi Y, Takeuchi A, Aranishi T, Morita S, Kuroi K, et al. Feasibility and validity of the Patient Neurotoxicity Questionnaire during taxane chemotherapy in a phase III randomized trial in patients with breast cancer: N-SAS BC 02. Support Care Cancer. 2009;17:1483–91.
Shimozuma K, Ohashi Y, Takeuchi A, Aranichi T, Morita S, Kuroi K, et al. Assessment and quantification of taxane-induced neurotoxicity in a phase III randomized trial of patients with breast cancer (AC followed by PAC/DOC vs. PAC/DOC alone): N-SAS BC 02. 2006 ASCO Annual Meeting 8523.
Ohsumi S, Shimozuma K, Ohashi Y, Takeuchi A, Suemasu K, Kuranami M, et al. Subjective and objective assessment of edema during adjuvant chemotherapy for breast cancer using taxane-containing regimens in a randomized controlled trial: the National Surgical Adjuvant Study of Breast Cancer 02. Oncology. 2012;82:131–8.
Aihara T, Takatsuka Y, Ohsumi S, Aogi K, Hozumi Y, Imoto S, et al. Phase III randomized adjuvant study of tamoxifen alone versus sequential tamoxifen and anastrozole in Japanese postmenopausal women with hormone-responsive breast cancer. N-SAS BC03 study. Breast Cancer Res Treat. 2010;121:379–87.
Hozumi Y, Suemasu K, Takei H, Aihara T, Takehara M, Saito T, et al. The effect of exemestane, anastrozole, and tamoxifen on lipid profiles in Japanese postmenopausal early breast cancer patients: final results of National Surgical Adjuvant Study BC 04, the TEAM Japan sub-study. Ann Oncol. 2011;22:1777–82.
Aihara T, Suemasu K, Takei H, Hozumi Y, Takehara M, Saito T, et al. Effects of exemestane, anastrozole and tamoxifen on bone mineral density and bone turnover markers in postmenopausal early breast cancer patients: results of N-SAS BC 04, the TEAM Japan Substudy. Oncology. 2011;79:376–81.
Fallowfield LJ, Leaity SK, Howell A, Benson S, Cella D. Assessment of quality of life in women undergoing hormonal therapy for breast cancer: validation of an endocrine symptom subscale for the FACT-B. Breast Cancer Res Treat. 1999;55:189–99.
Radloff LS. The CES-D scale. A self-report depression scale for research in the general population. Appl Psychol Meas. 1977;1:385–401.
Ohsumi S, Shimozuma K, Ohashi Y, Shinji M, Hozumi Y, Mukai H, et al. Health-related quality of life and psychological distress of breast cancer patients after surgery during a phase III randomized trial comparing continuation of tamoxifen with switching to anastrozole after adjuvant tamoxifen for 1 to 4 years: N-SAS BC 03. Breast Cancer Res Treat. 2011;127:143–52.
Takei H, Ohsumi S, Shimozuma K, Takehara M, Suemasu K, Ohashi Y. Health-related quality of life, psychological distress, and adverse events in postmenopausal women with breast cancer who receive tamoxifen, exemestane, or anastrozole as adjuvant endocrine therapy: National Surgical Adjuvant Study of Breast Cancer 04 (N-SAS BC 04) Breast Cancer Res Treat. 2012 (Epub ahead of print).
Fallowfield L, Cella D, Cuzick J, Francis S, Locker G, Howell A. Quality of life of postmenopausal women in the Arimidex, Tamoxifen, Alone or in Combination (ATAC) Adjuvant Breast Cancer Trial. J Clin Oncol. 2004;22:4261–71.
Cella D, Fallowfield L, Barker P, Cuzick J, Locker G, ATAC Trialists’ Group. Quality of life of postmenopausal women in the ATAC (“Arimidex”, tamoxifen, alone or in combination) trial after completion of 5 years’ adjuvant treatment for early breast cancer. Breast Cancer Res Treat. 2006;100:273–84.
Fallowfield LJ, Bliss JM, Porter LS, Price MH, Snowdon CF, Jones SE, et al. Quality of life in the Intergroup Exemestane Study: A randomized trial of exemestane versus continued tamoxifen after 2 to 3 years of tamoxifen in postmenopausal women with primary breast cancer. J Clin Oncol. 2006;24:910–7.
Whelan TJ, Goss PE, Ingle JN, Pater JL, Tu D, Pritchard K, et al. Assessment of quality of life in MA. 17: a randomized, placebo-controlled trial of letrozole after 5 years of tamoxifen in postmenopausal women. J Clin Oncol. 2005;23:6931–40.
Iwata H, Masuda N, Toyama T, Taira N, Yamamoto Y, Saji S, et al. A phase III study of adjuvant endocrine therapy with or without chemotherapy for postmenopausal breast cancer patients who responded to neoadjuvant letrozole: study design of the New Primary Endocrine-Therapy Origination Study [NEOS (N-SAS BC 06)]. 2009 St. Gallen Consensus Meeting P174.
Sawaki M, Tokudome N, Mizuno T, Nakayama T, Taira N, Bando H, et al. Evaluation of trastuzumab without chemotherapy as a post-operative adjuvant therapy in HER2-positive elderly breast cancer patients: randomized controlled trial [RESPECT (N-SAS BC07)]. Jpn J Clin Oncol. 2011;41:709–12.
Ware JE, Kosinski M, Dewey JE. How to score version two of the SF-36 Health Survey. Lincoln: QualityMetric, Incorporated; 2000.
Yagata H, Iwase T, Ohtsu H, Komoike Y, Saji S, Takei H, et al. Baseline assessment of patient-reported outcomes (PROs) for breast cancer patients after 5 years of endocrine treatment in a randomized clinical trial: NSAS-BC 05. 2011 St. Gallen Consensus Meeting P284.
Zigmond AS, Snaith RP. The hospital anxiety and depression scale. Acta Psychiatr Scand. 1983;67:361–70.
Lawton MP. The Philadelphia Geriatric Center Morale Scale: a revision. J Gerontol. 1975;30:85–9.
Folstein MF, Folstein SE, McHugh PR. “Mini-Mental State”. A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res. 1975;12:189–98.
Mukai H, Takashima T, Hozumi Y, Watanabe T, Murakami S, Masuda N, et al. Randomized study of taxane versus TS-1 in women with metastatic or recurrent breast cancer (SELECT BC). Jpn J Clin Oncol. 2010;40:811–4.